elzonris
stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastilised ained - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).
spectrila
medac gesellschaft fuer klinische spezialpraeparate mbh - asparaginaas - prekursorko-lümfoblastne leukeemia-lümfoom - antineoplastilised ained - spectrila on näidustatud osana antineoplastilised kombineeritud ravi ägeda lümfoblastse leukeemia (all lastel alates sünnist kuni 18 aastat ja täiskasvanute) raviks.
imprida
novartis europharm ltd - valsartan, amlodipine (as amlodipine besilate) - hüpertensioon - reniini-angiotensiini süsteemi toimivad ained - essentsiaalse hüpertensiooni ravi. imprida on näidustatud patsientidele, kelle vererõhk ei ole adekvaatselt kontrollitav kohta amlodipine või valsartan monotherapy.
orfiril long 1000 mg toimeainet prolongeeritult vabastavad graanulid
desitin arzneimittel gmbh - valproehape - toimeainet prolongeeritult vabastavad graanulid - 1000mg 100tk
orfiril süstelahus
desitin arzneimittel gmbh - valproehape - süstelahus - 100mg 1ml 3ml 5tk
carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - mitu müeloomit - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
onduarp
boehringer ingelheim international gmbh - telmisartan - hüpertensioon - kardiovaskulaarsüsteem - ravi oluline hüpertensioon täiskasvanud:lisada therapyonduarp on näidustatud täiskasvanutel, kelle vererõhk ei ole adekvaatselt kontrollitav kohta amlodipine. asendamine therapyadult saavate patsientide telmisartan ja amlodipine alates eraldi tablette võib selle asemel saada tabletid onduarp sisaldavad sama komponendi doosid.
fingolimod mylan
mylan ireland limited - fingolimod vesinikkloriid - sclerosis multiplex, relapsing-remitting - immunosupressandid - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ja 5. 1)orpatients kiiresti arenev raske relapsing remitting sclerosis multiplex määratud 2 või enam puuet ägenemiste ühe aasta, ja on 1 või enam gadoliinium suurendada kahjustused aju mri või olulist kasvu, t2 kahjustus koormus võrreldes varasema hiljutise mrt.
fingolimod mylan
mylan ireland limited - fingolimod vesinikkloriid - sclerosis multiplex, relapsing-remitting - immunosupressandid - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ja 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
mifegyne tablett
exelgyn - mifepristoon - tablett - 200mg 15tk; 200mg 1tk; 200mg 3tk